Volume | 1,077,504 |
|
|||||
News | - | ||||||
Day High | 105.14 | Low High |
|||||
Day Low | 102.27 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Moderna Inc | MRNA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
104.51 | 102.27 | 105.14 | 103.79 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
23,385 | 1,077,504 | $ 103.89 | $ 111,938,583 | - | 62.55 - 156.75 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
14:51:20 | 1 | $ 103.39 | USD |
Moderna (MRNA) Options Flow Summary
Moderna Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
39.5B | 382.07M | - | 6.85B | -4.71B | -12.34 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Moderna News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MRNA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 107.75 | 110.14 | 102.27 | 105.67 | 2,636,230 | -4.36 | -4.04% |
1 Month | 103.41 | 115.89 | 97.00 | 106.37 | 3,357,693 | -0.015 | -0.01% |
3 Months | 103.41 | 115.89 | 84.06 | 100.38 | 3,843,197 | -0.015 | -0.01% |
6 Months | 90.51 | 115.97 | 62.55 | 92.61 | 4,574,966 | 12.89 | 14.24% |
1 Year | 156.60 | 156.75 | 62.55 | 103.69 | 4,098,084 | -53.21 | -33.98% |
3 Years | 166.79 | 497.17 | 62.55 | 219.49 | 7,063,664 | -63.40 | -38.01% |
5 Years | 24.00 | 497.17 | 11.54 | 147.54 | 8,832,197 | 79.40 | 330.81% |
Moderna Description
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. |